Target intelligence / Profile preview

HIV-1 polymerase polyprotein (Pol) (Pol)

Target
Pol
Molecular classification
Enzyme, Aspartic protease, RNA-directed DNA polymerase, DNA-directed DNA polymerase, Ribonuclease H, Integrase
01

Overview

The HIV-1 polymerase polyprotein, encoded by the pol gene, is a multifunctional precursor essential for the replication and maturation of the Human Immunodeficiency Virus type 1 [1]. It is expressed as a Gag-Pol fusion protein through a ribosomal frameshift and is subsequently processed by the viral protease into three distinct enzymes: protease (PR), reverse transcriptase (RT), and integrase (IN) [2]. Reverse transcriptase converts the viral RNA genome into double-stranded DNA, while integrase facilitates the insertion of this DNA into the host cell's genome [3]. The protease is responsible for cleaving the Gag and Gag-Pol polyproteins into functional structural and enzymatic proteins, a step vital for the production of infectious virions [4]. Due to its indispensable role in the viral life cycle, the Pol polyprotein and its derived enzymes are the primary targets of modern antiretroviral therapy (ART) [3]. Drugs such as reverse transcriptase inhibitors, integrase strand transfer inhibitors, and protease inhibitors are used in combination to suppress viral replication and prevent the progression to AIDS [5]. Resistance to these drugs often arises through specific mutations within the pol gene, necessitating continuous monitoring and the development of next-generation inhibitors [1].

Other names
HIV-1 pol gene productGag-Pol polyproteinPolymerase polyproteinReverse transcriptase-protease-integrase polyprotein
02

Mechanism of action

Inhibition of reverse transcription (via chain termination or allosteric inhibition), inhibition of viral DNA integration into the host genome, and inhibition of proteolytic cleavage of viral polyproteins.

03

Biological functions

Viral replicationReverse transcriptionDNA integrationProteolysisViral maturation
04

Disease associations

InfectionAcquired Immunodeficiency Syndrome (AIDS)
05

Safety considerations

Emergence of drug-resistant viral strainsMitochondrial toxicityLipodystrophy and metabolic disturbancesHepatotoxicitySignificant drug-drug interactions via CYP3A4
06

Interacting drugs

Zidovudine

16 more in the full profile.

07

Biomarkers

Plasma HIV-1 RNA (viral load)CD4+ T-cell countPol gene resistance mutations (e.g., K103N, M184V, Q148H)

Beyond the preview

Go deeper on HIV-1 polymerase polyprotein (Pol) (Pol).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on HIV-1 polymerase polyprotein (Pol) (Pol).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call